Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human IFN alpha ProQuantum Immunoassay Kit


Click to view available options
Quantity:
5 x 96 Tests
96 Tests
Description
IFN alpha (Interferon alpha) is a Type I interferon belonging to a family of structurally related, species-specific proteins exclusive to vertebrates. The interaction of IFN-alpha with its receptor component result in the activation of a number of signaling pathways which are mainly involved in innate immune response against viral infection. In humans, the gene for IFN alpha is located on on chromosome 9. The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms. Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species. IFN alpha is produced primarily by plasmacytoid dendritic cells, is a potent component of the anti-viral innate immune response and modulates adaptive immunity. Diseases associated with the dysfunction of IFN alpha include Hepatitis C and Hepatitis.

Specifications
Specifications
Accession Number | P01562 |
Assay Range | 0.064 to 5000 pg/mL |
Assay Sensitivity | <0.05 pg/mL |
Conjugate | FAM™ |
Detection Method | Taqman™ Real-time PCR |
Immunoassay Kit Format | Proximity-based Immunoassay |
Product Type | ProQuantum |
Sample Type | Plasma, Serum, Supernatant |
Target Species | Human |
For Use With (Application) | Protein Quantitation |
Show More |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction